FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295038> ?p ?o ?g. }

• W4286295038 endingPage "6589" @default.
• W4286295038 startingPage "6589" @default.
• W4286295038 abstract "6589 Background: Real-world utilization and comparative effectiveness of direct oral anticoagulants (DOACs), low molecular weight heparin (LMWH) and warfarin for cancer-associated venous thromboembolism (VTE) treatment remains largely unexplored. Methods: De-identified administrative claims data (OptumLabs - Data Warehouse) for adult active cancer patients with acute VTE (1/1/2012-9/30/2019) were assessed for utilization patterns, recurrent VTE, and major bleeding differences between DOACs, LMWH, and warfarin. Patients were followed up till the end of treatment. Patients who crossed over to other anti-coagulants within the follow up period were excluded. Multinomial logistic regression was used to assess predictors of anticoagulant administration. Kaplan-Meier curves were used to evaluate the differences in time to medication discontinuation among the three groups. Propensity score (PS) and inverse probability of treatment weighting were used to balance baseline differences between groups. Standardized difference (SD) was used to assess the balance of covariates after weighting and SD < 10% was considered acceptable. Weighted Cox proportional hazards regression with a robust variance estimator was then used to assess outcomes in PS weighted groups. Results: A total of 5100 patients met the inclusion criteria; 49.3% filled DOACs (n = 2512), 29.2% LMWH (n = 1488), and 28.6% warfarin (n = 1460). Median treatment duration was around 3.2 months for DOACs and warfarin, and 1.8 months for LWMH ( P-value < 0.01). Multinomial regression analysis showed that younger patients were more likely to be prescribed LMWH (OR 0.97 95% CI: 0.97-0.98) as compared to DOACs. Patients with lung (OR 2.07 95% CI: 1.12-3.65; OR 1.87 95% CI: 1.04-3.37), urological (OR: 1.94 95% CI:1.08-3.49; OR: 2.04 95% CI: 1.12-3.73), gynecological (OR 4.25, 95% CI: 2.31-7.82; OR 2.31 95% CI: 1.22-4.39) and colorectal cancer (OR 2.26 95% CI: 1.20-4.32; OR 2.51; 95% CI: 1.32-4.79) were more likely to be prescribed LMWH or warfarin respectively, compared to DOACs. VTE recurrences were more frequent for patients receiving LMWH (HR: 1.47; 95% CI: 1.14-1.90) or warfarin (HR: 1.46; 95% CI: 1.13-1.87) compared to DOACs. LMWH, but not warfarin, was associated with greater major bleeding rates compared to DOACs (HR: 2.27; 95% CI: 1.62-3.20). All-cause mortality rates were also significantly higher for patients receiving LMWH, but not warfarin compared to DOACs (HR: 1.61; 95% CI: 1.15-2.25). Conclusions: Patients with cancer associated VTE remain on anti-coagulation for a remarkably short duration in real-world clinical practice. DOACs and warfarin may offer better compliance than LMWH. Patients receiving DOACs have a lower risk of VTE recurrence, less major bleeding, and improved mortality. Warfarin may still be considered for patients with contraindications to DOACs and non-compliant to LMWH." @default.
• W4286295038 created "2022-07-21" @default.
• W4286295038 creator A5017032740 @default.
• W4286295038 creator A5018306647 @default.
• W4286295038 creator A5020149556 @default.
• W4286295038 creator A5021574576 @default.
• W4286295038 creator A5048391277 @default.
• W4286295038 creator A5050586204 @default.
• W4286295038 creator A5060027910 @default.
• W4286295038 creator A5067550666 @default.
• W4286295038 creator A5069388227 @default.
• W4286295038 date "2022-06-01" @default.
• W4286295038 modified "2023-10-18" @default.
• W4286295038 title "Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis." @default.
• W4286295038 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.6589" @default.
• W4286295038 hasPublicationYear "2022" @default.
• W4286295038 type Work @default.
• W4286295038 citedByCount "0" @default.
• W4286295038 crossrefType "journal-article" @default.
• W4286295038 hasAuthorship W4286295038A5017032740 @default.
• W4286295038 hasAuthorship W4286295038A5018306647 @default.
• W4286295038 hasAuthorship W4286295038A5020149556 @default.
• W4286295038 hasAuthorship W4286295038A5021574576 @default.
• W4286295038 hasAuthorship W4286295038A5048391277 @default.
• W4286295038 hasAuthorship W4286295038A5050586204 @default.
• W4286295038 hasAuthorship W4286295038A5060027910 @default.
• W4286295038 hasAuthorship W4286295038A5067550666 @default.
• W4286295038 hasAuthorship W4286295038A5069388227 @default.
• W4286295038 hasConcept C126322002 @default.
• W4286295038 hasConcept C151956035 @default.
• W4286295038 hasConcept C17923572 @default.
• W4286295038 hasConcept C2776301958 @default.
• W4286295038 hasConcept C2778715236 @default.
• W4286295038 hasConcept C2779161974 @default.
• W4286295038 hasConcept C50382708 @default.
• W4286295038 hasConcept C71924100 @default.
• W4286295038 hasConceptScore W4286295038C126322002 @default.
• W4286295038 hasConceptScore W4286295038C151956035 @default.
• W4286295038 hasConceptScore W4286295038C17923572 @default.
• W4286295038 hasConceptScore W4286295038C2776301958 @default.
• W4286295038 hasConceptScore W4286295038C2778715236 @default.
• W4286295038 hasConceptScore W4286295038C2779161974 @default.
• W4286295038 hasConceptScore W4286295038C50382708 @default.
• W4286295038 hasConceptScore W4286295038C71924100 @default.
• W4286295038 hasIssue "16_suppl" @default.
• W4286295038 hasLocation W42862950381 @default.
• W4286295038 hasOpenAccess W4286295038 @default.
• W4286295038 hasPrimaryLocation W42862950381 @default.
• W4286295038 hasRelatedWork W1998907014 @default.
• W4286295038 hasRelatedWork W2042797600 @default.
• W4286295038 hasRelatedWork W2047820770 @default.
• W4286295038 hasRelatedWork W2332670854 @default.
• W4286295038 hasRelatedWork W2429537896 @default.
• W4286295038 hasRelatedWork W2471192659 @default.
• W4286295038 hasRelatedWork W2883573830 @default.
• W4286295038 hasRelatedWork W3002298057 @default.
• W4286295038 hasRelatedWork W3007385212 @default.
• W4286295038 hasRelatedWork W3185856855 @default.
• W4286295038 hasVolume "40" @default.
• W4286295038 isParatext "false" @default.
• W4286295038 isRetracted "false" @default.
• W4286295038 workType "article" @default.